Acadian Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Acadian Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-576,762	Closed	-$8.21M	–	2089
2025 Q4	$8.21M	Buy	576,762 +446,330	+342%	+$4.38M	0.01%	524
2025 Q3	$1.02M	Buy	130,432 +56,517	+76%	+$402K	﹤0.01%	1048
2025 Q2	$422K	Buy	+73,915	New	+$477K	﹤0.01%	1170
2024 Q4	–	Sell	-28,229	Closed	-$301K	–	1811
2024 Q3	$301K	Buy	+28,229	New	+$307K	﹤0.01%	1230
2021 Q1	–	Sell	-3,406	Closed	-$79K	–	2149
2020 Q4	$79K	Buy	+3,406	New	+$69.7K	﹤0.01%	1821
2017 Q4	–	Sell	-446	Closed	-$7K	–	1610
2017 Q3	$7K	Buy	+446	New	+$5.9K	﹤0.01%	1300
2015 Q4	–	Sell	-142	Closed	-$2K	–	1441
2015 Q3	$2K	Buy	+142	New	+$2.23K	﹤0.01%	1254

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Acadian Asset Management's FOLD Position: Q1 2026 in Review

Acadian Asset Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 576,762 shares — an estimated $8.21M sold.

Acadian Asset Management first reported a position in FOLD in Q3 2015 and held it in 7 quarters. The position peaked at $8.21M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Acadian Asset Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Acadian Asset Management sold 576,762 Amicus Therapeutics shares in Q1 2026, an estimated $8.21M.
Acadian Asset Management first reported a position in Amicus Therapeutics in Q3 2015 and held it in 7 quarters.
Acadian Asset Management's Amicus Therapeutics position peaked at $8.21M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.